With healthier finances, Clover Bio shifts to flu and RSV vaccines
The Chinese vaccine developer rebounded from a deep loss into profit in the first half of the year, boosted by a one-off gain from a Covid research grant Key Takeaways:…
Recent Articles
RECENT ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
